News & Updates
Filter by Specialty:
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
Smoking, obesity, treatment duration, and pre-existing cardiac diseases may contribute to the development of cardiotoxicity among patients with cancer who are undergoing 5-fluorouracil (5-FU) chemotherapy, suggests a recent study.
Obesity, smoking tied to 5-FU-induced cardiotoxicity in cancer patients
29 Sep 2025
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
29 Sep 2025
Semaglutide, dulaglutide help prevent cognitive decline in HF patients
Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.
